Fangsheng Pharmaceutical: Indobufen Tablets and Bisoprolol Amlodipine Tablets are expected to be selected in the Twelfth National Centralized Procurement.

Fangsheng Pharmaceuticals announced that its product Indobufen Tablets and its wholly-owned subsidiary Fangsheng Jianmeng's product Bisoprolol and Amlodipine Tablets are expected to be selected for the 12th batch of the national organization for centralized procurement of medicines, with the procurement period ending on December 31, 2029. The above products have not yet been officially sold and have no sales data.